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Cirrhosis is a leading cause of death worldwide. The rising global
burden of cirrhosis and its complications is the focus of much
attention in Europe, the US and elsewhere [1,2]. In the US, it is
the eighth leading cause of death affecting approximately
5.5 million patients at an annual cost of >$1.5 billion [3], which
is expected to rise further in the next 10 years due to aging hep-
atitis C populations [4]. A similar trend is observed in Western
Europe [5]. About 50–60% of patients with compensated cirrhosis
will develop ascites within a decade at a 5-year survival rate of
50% (excluding liver transplant patients) [6,7]. Patients with cir-
rhosis are prone to develop a number of often predictable and
treatable, but costly, complications including ascites, spontane-
ous bacterial peritonitis (SBP), renal failure and hepatic encepha-
lopathy [8]. Up to 69% of patients with decompensated cirrhosis
required at least one non-elective hospital readmission within a
median time of about two months to the ﬁrst admission [8]. Con-
sequently, such patients with decompensated cirrhosis require
close and specialized medical care. Regretfully, the quality of care
given to such patients is at best suboptimal. A recent study by
Kanwal et al. measured quality of care indicators in 774 patients
with cirrhosis and ascites [9]. The results of this survey suggest
that only 33% of patients received all guidelines recommended
care, with quality scores ranging from 30% for secondary prophy-
laxis of SBP to 90% for cell counts in the ascitic ﬂuid. Moreover,
only 30% of patients with SBP were prescribed antibiotics for sec-
ondary prophylaxis within 30 days of discharge and only 49% of
patients with bleeding esophageal varices received prophylactic
antibiotics. The reasons for the failure of the healthcare system
to provide better care to these patients are further discussed in
an editorial by M. Volk, written in response to the publication
by Kanwal et al. [9,10]. As with other medical conditions, the
quality of care for patients with cirrhosis is mainly driven by
the knowledge and competence of both the primary care physi-
cian and the hepatologist as well as the patient’s compliance,
but, not less important, by the structure of the healthcare system.Journal of Hepatology 20
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Open access under CC BY-NC-ND license.Quoting Dr Volk in his editorial ‘How can we improve quality of
care for patients with cirrhosis’ [10]: ‘‘The majority of the deﬁcit
may lie in the structure of our healthcare system which is episodic,
symptom driven and reactive rather than proactive and better suited
for treating acute issues than chronic conditions. . .’’.
In the present issue of the Journal, Dr Morando and co-
workers from Padua, address the need for improvement in
the structure of the health care system for cirrhotic patients
with ascites [11]. The authors suggest a new model for special-
ized care giving for ambulatory cirrhotic patients with ascites
(which most probably is also applicable to other complications
of decompensated liver disease) which leads to a signiﬁcant
reduction in the
12-month mortality as well as the overall cost of care.
Brieﬂy, 100/110 candidate patients with cirrhosis and ascites
were recruited consecutively and were allocated in an alternate,
non-randomized fashion upon discharge from hospitalization to
either a newly designated ‘‘care management check-up’’ group
(group 1), N = 40; or to a ‘‘standard of care’’ outpatient group
(group 2), N = 60. Groups were matched for age, gender, type of
ascites, MELD score, CTP score, etiology of cirrhosis, place of res-
idence and co-morbidities based on the Charlson index.
Group 1 was followed by a team of hepatologists and dedi-
cated nurses at a hospital outpatient clinic. They had rapid, same
day access to specialized procedures as well as blood and urine
test including ultrasound, gastroscopy, EEG, and psychometric
testing. Based on same-day-obtained results of the investigation
(hospital stay of 5–9 hours), patients received speciﬁc dietary
and pharmacologic instructions; were rescheduled for a new
clinic visit within 1–12 weeks and the new results and recom-
mendations forwarded to the primary care physician.
Group 2 (the control group) patients were referred after hospi-
tal discharge to the general, primary care practitioner, to be fol-
lowed and treated according to existing guidelines with
potential support ‘‘on demand’’ from a specialized physician. Lab-
oratory tests and interventional procedures were available to this
group through elective appointments.
Patients from both groups had access to a day hospital for
invasive procedures including banding/ligation of varices, par-
centesis or transfusion.
The main results of this study reveal that the 12-month mor-
tality in group 2, who had no direct access to specialized care,
was almost twice as high as compared to group 1, reaching13 vol. 59 j 201–202
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45.7% and 23.1%, respectively (p <0.025). Furthermore, hospital
readmission rates were more than twice higher for group 2,
reaching 42.4% vs. 15.4% in group 2 and 1, respectively. Finally,
the overall cost for management per patient-month of life was
about 50% lower for group 1, reaching 1479 Euro as compared
to 2816 Euro for group 2 (p <0.05). The costs for the specialized
care given to group 1, as well as costs for coverage of day-hospi-
tal, were signiﬁcantly higher as compared to the conventional
group 2. However, the costs for hospital stay including emer-
gency readmission of group 2 were higher as compared to group
2, thus the global expense was higher for group 2.
The conclusions of the study by Morando et al. suggest that
the management model for group 1, which requires the place-
ment of a dedicated specialized team for care of cirrhotic patients
with ascites, can delay complications, improves quality of life and
survival, and is cost effective. Thus, the results of this study
provide some answers to the questions raised in the editorial
by M. Volk, suggesting a change in the structure of medical care
offered to cirrhotic patients using a preemptive pro-active
approach. It is still not clear if the conclusions regarding overall
cost effectiveness ﬁt only the Italian healthcare system or are
applicable in other countries with a different healthcare system
structure or specialized day care facilities for patients with liver
disease. In some countries, ﬁnancial coverage for ambulatory care
and hospitalization is funded by different insurance providers
and such fragmentation will require better coordination between
agencies to reach a similar cost saving outcome. In other coun-
tries (i.e., Israel), some specialized outpatient clinics and day care
facilities are restricted by the insurer in ordering elective investi-
gations in the hospital, such as endoscopy, ultrasound examina-
tion, or special blood tests in stable patients whom they prefer
to evaluate in their own facilities. However, regardless of these
bureaucratic hurdles and some limitations mentioned by the
authors in the discussion, the results of this study provide con-
vincing evidence that the Italian model from Padua, of specialized
and rapid management of cirrhotic patients with ascites with
easy access to diagnostic facilities and counseling, contributes202 Journal of Hepatology 201signiﬁcantly to the quality of life and one-year survival of
patients with cirrhosis and ascites.Conﬂict of interest
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